Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | June 01, 2026 | June 03, 2026 |
| ONCOLYTICS BIOTECH INCONCY · Entity 6721 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 51,189 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 51,189 · Balance 51,189 F1: Scheduled to vest in four substantially equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest in four substantially equal quarterly installments.
ONCOLYTICS BIOTECH INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2036-06-01 | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2030-12-23 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 180,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2029-11-07 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Disposition to issuer · Disposed 94,792 · Balance 0 F2: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2028-11-08 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-17 · Disposition to issuer · Disposed 59,896 · Balance 0 F3: The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2026-11-09 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-17 · Disposition to issuer · Disposed 5,761 · Balance 0 F4: The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2024-04-17 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-17 · Disposition to issuer · Disposed 36,204 · Balance 0 F5: The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.65 · Expires 2027-11-09 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-17 · Disposition to issuer · Disposed 24,390 · Balance 0 F6: The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.04 · Expires 2026-05-27 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-17 · Disposition to issuer · Disposed 30,171 · Balance 0 F7: The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.27 · Expires 2025-11-19 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-17 · Disposition to issuer · Disposed 30,171 · Balance 0 F8: The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
F2: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F3: The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F4: The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F5: The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F6: The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F7: The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F8: The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-26-027089 · ownership.xml · derivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:24 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 51,189 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001759855-26-000004 · form4-06032026_090621.xml · derivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,189 Underlying: Voting Common Shares · 51,189 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest in four substantially equal quarterly installments. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 10,000 | $1.03 | $10,300.00 |
DisclosureSEC source: 0001493152-26-009983 · ownership.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,849 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:24 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantCommon Stock | 10,095 | $8.42 | $84,999.90 |
DisclosureSEC source: 0001759855-26-000002 · form4-01062026_100130.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,949 F1 · shares: Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:30 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001759855-25-000006 · form4-11252025_091152.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,000 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the conversion of the exercise price from CAD$ to US$ on the transaction date. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:30 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | Exercise / conversionCommon Stock | 12,000 | $2.20 | $26,400.00 |
DisclosureSEC source: 0001759855-25-000006 · form4-11252025_091152.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the conversion of the exercise price from CAD$ to US$ on the transaction date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:17 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 40,739 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019293 · rdgdoc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,739 Underlying: Common Shares · 40,739 shares Expires 2035-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:46 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 4,287 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001235802-25-000005 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,287 Underlying: Common Shares · 4,287 shares Expires 2035-01-01 F3 · derivative.exercise_date: Vests in two nearly equal installments on each of March 1, 2025 and June 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:46 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 15,917 | $5.34 | $84,996.78 |
DisclosureSEC source: 0001235802-25-000005 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,854 F1 · shares: These shares are issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000047 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:39 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 21,428 | $2.80 | $59,998.40 |
DisclosureSEC source: 0001235802-24-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,937 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 53,837 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 16,968 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000058 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,968 Underlying: Common Shares · 16,968 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:44 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000072 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 16,773 | $3.58 | $60,047.34 |
DisclosureSEC source: 0001235802-22-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,509 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000. F2 · balance_after: Amount reflects the cancellation of 211 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships. F3 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 32,409 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,171 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 8 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,171 shares Expires 2025-11-19 F8 · derivative.exercise_price: The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,171 | $0.00 Strike: $11.04 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 7 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,171 shares Expires 2026-05-27 F7 · derivative.exercise_price: The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,390 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 6 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 24,390 shares Expires 2027-11-09 F6 · derivative.exercise_price: The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,204 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 5 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 36,204 shares Expires 2024-04-17 F5 · derivative.exercise_price: The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,761 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 4 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,761 shares Expires 2026-11-09 F4 · derivative.exercise_price: The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 59,896 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 3 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 59,896 shares Expires 2028-11-08 F3 · derivative.exercise_price: The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 94,792 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 94,792 shares Expires 2029-11-07 F2 · derivative.exercise_price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:29 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001104659-21-141747 · tm2133436-5_4seq1.xml · derivative · entry 1 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 180,000 shares Expires 2030-12-23 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:45 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 9,393 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000081 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,393 Underlying: Common Shares · 9,393 shares Expires 2031-07-14 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,505 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0001062993-21-000293 · form4.xml · derivative · entry 3 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,761 Underlying: Common Shares · 8,505 shares Expires 2026-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | SaleCommon Shares | 8,505 | $15.79 | $134,270.99 |
DisclosureSEC source: 0001062993-21-000293 · form4.xml · nonDerivative · entry 2 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $15.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 8,505 | $7.24 | $61,616.17 |
DisclosureSEC source: 0001062993-21-000293 · form4.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 21:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 7,745 | $8.23 | $63,741.35 |
DisclosureSEC source: 0001235802-21-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,947 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $63,750. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 15,847 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:49 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 13,306 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000050 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,306 Underlying: Common Shares · 13,306 shares Expires 2030-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:49 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 8,102 | $4.59 | $37,188.18 |
DisclosureSEC source: 0001235802-20-000050 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,202 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $37,188. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:36 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 12,950 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000063 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 Underlying: Common Shares · 12,950 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:27 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 2,250 | $4.00 | $9,000.00 |
DisclosureSEC source: 0001235802-18-000181 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 F1 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.